Ganli Pharmaceutical (603087.SH) released its 2023 annual report, achieving revenue of 2,608 billion yuan, an increase of 52.31% over the previous year. Achieved net profit of 340 million yuan attributable to shareholders of listed companies, turning a year-on-year loss into a profit. Achieved net profit of 297 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, turning losses into profits over the previous year. It is proposed to distribute a cash dividend of 2 yuan (tax included) for every 10 shares to all shareholders.